Oct 14,2021

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced Solid Tumors

Aug 13,2021

Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients with Advanced Solid Tumors

Aug 05,2021

Apexigen Receives Orphan Drug Designation from the FDA for Sotigalimab (APX005M) for the Treatment of Soft Tissue Sarcoma

Jul 23,2021

Cytek Biosciences Announces Pricing of Its Initial Public Offering

Jul 19,2021

Cell analysis instruments provider Cytek BioSciences sets terms for $248 million IPO

Jul 15,2021

Aravive Achieves Second Development Milestone from 3D Medicines

Jul 01,2021

Twist Bioscience Acquires NGS Library Preparation Maker iGenomX

Jun 16,2021

KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension

No more pages to load

Next page